Dalteparin Sodium

CHEMBL1201460 Phase 4 Aprobado Oligosaccharide
Half-Life
Bioavailability
Protein Binding
Molecular Weight
g/mol
LogP
Phase
4

A low-molecular-weight heparin that prevents and treats blood clots by inhibiting factor Xa and thrombin in the coagulation cascade. It is injected subcutaneously and used for deep vein thrombosis, pulmonary embolism prevention, and extended venous thromboembolism treatment in cancer patients.

Áreas terapéuticas

Mecanismo de acción

Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose administered.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose …

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

A low-molecular-weight heparin that prevents and treats blood clots by inhibiting factor Xa and thrombin in the coagulation cascade. It is injected subcutaneously and used for deep vein thrombosis, pulmonary embolism prevention, and extended venous thromboembolism treatment in cancer patients.

Binds to antithrombin III, dramatically accelerating its inhibition of thrombin (Factor IIa), Factor Xa, and other serine proteases of the coagulation cascade. This produces rapid anticoagulation proportional to the dose administered.

Yes, Dalteparin Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Oligosaccharide.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201460. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.